Bank of America Securities analyst Tim Anderson reiterated a Buy rating on Metsera, Inc. (MTSR – Research Report) today and set a price target ...

In a compelling validation of InvestingPro’s Fair Value analysis capabilities, Metsera , Inc. (NASDAQ:MTSR) has declined 44% since being identified as significantly overvalued by our proprietary ...

In a compelling validation of InvestingPro’s Fair Value analysis capabilities, Metsera , Inc. (NASDAQ:MTSR) has declined 44% since being identified as significantly overvalued by our proprietary ...

Despite several big deals that buoyed the numbers, North America early- and seed-stage investment declined to multiquarter ...

Metsera is leaving no fundraising stone unturned as it races to grab a slice of the fast-growing market for obesity drugs. Just nine months after emerging from stealth with a $290 million Series A ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.